MGI PHARMA
MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care applications. The company markets its products through sales organizations in the United States, as well as alliances with other pharmaceutical or biotechnology companies internationally. MGI PHARMA, INC. was founded in 1979 as Molecular Genetics, Inc. and changed its name to MGI PHARMA, INC. in 1990. The company is headquartered in Bloomington, Minnesota. It has facilities in Bloomington, Minnesota; Lexington, Massachusetts; and Baltimore, Maryland. As of January 25, 2008, MGI PHARMA, INC. operates as a subsidiary of Eisai Corporation of North America.
MGI PHARMA
Industry:
Biotechnology
Founded:
1979-01-01
Address:
Bloomington, Minnesota, United States
Country:
United States
Status:
Active
Similar Organizations
AnorMED
AnorMED, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic drugs.
Theratechnologies
Theratechnologies is a a bio-pharmaceutical company, engages in the discovery of therapeutic products for commercialisation.
Current Employees Featured
More informations about "MGI Pharma"
MGI Pharma - Crunchbase Company Profile & Funding
MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceutical products for oncology and acute care …See details»
MGI Pharma Company Profile 2024: Valuation, Investors
Information on acquisition, funding, investors, and executives for MGI Pharma. Use the PitchBook Platform to explore the full profile.See details»
MGI Pharma Inc - Company Profile and News - Bloomberg …
MGI Pharma, Inc. is an oncology-focused biopharmaceutical company that acquires, develops, and markets specialty pharmaceutical and medical products for therapeutic markets of unmet...See details»
EISAI COMPLETES ACQUISITION OF MGI PHARMA
Tokyo, Japan, January 28, 2008 (U.S. Time) - Eisai Co., Ltd. (Tokyo, TSE 4523) (“Eisai”), a research-based human health care (hhc) company, today announced the successful …See details»
MGI Pharma - Products, Competitors, Financials, …
MGI Pharma is an oncology-focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of cancer patients. Use the …See details»
ALOXI® (PALONOSETRON HCL) INJECTION …
Jul 9, 2008 · The introduction of ALOXI for PONV represents the first launch with an additional indication of an MGI PHARMA, INC. product since Eisai acquired the organization in January …See details»
Eisai To Acquire MGI Pharma - Chemical & Engineering News
Dec 17, 2007 · MGI Pharma's Aloxi for chemotherapy-induced nausea could reach $750 million in peak sales. JAPAN'S EISAI, looking to enhance its pipeline and increase its presence in the …See details»
MGI Pharma - Contacts, Employees, Board Members, …
MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceuticalSee details»
MGI PHARMA Company Profile | Baltimore, MD - Dun
Find company research, competitor information, contact details & financial data for MGI PHARMA of Baltimore, MD. Get the latest business insights from Dun & Bradstreet.See details»
Eisai buys MGI Pharma for $3.9bn - Financial Times
Dec 11, 2007 · Eisai on Monday said it would buy US biotech firm MGI Pharma for $3.9bn (£1.9bn, €2.6bn) in the largest ever overseas all-cash acquisition by a Japanese pharma …See details»
MGI Pharma buys Guilford in $178M deal
Jul 24, 2005 · US firm MGI Pharma and Guilford Pharmaceuticals have signed a definitive merger agreement providing for the acquisition of the latter in a cash and stock deal valued at $178.0 …See details»
Japan's Eisai Buying MGI Pharma For $3.9 Billion
Dec 10, 2007 · TOKYO (AP) — Japanese drugmaker Eisai Co. said Monday it will buy U.S. biopharmaceutical company MGI Pharma Inc. for $3.9 billion in cash in a move aimed at …See details»
MGI Pharma | Insights
Mar 15, 2024 · Agilent Technologies and Hologic added two more deals to the growing list of major acquisitions in the in vitro diagnostics market in 2021. On 2 March, Agilent announced a …See details»
MGI Pharma - Tech Stack, Apps, Patents & Trademarks
MGI PHARMA, INC., a biopharmaceutical company, engages in the acquisition, research, development, and commercialization of pharmaceuticalSee details»
Mgi Pharma : Dacogen(TM) (Decitabine) For Injection …
Aug 1, 2006 · (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that the European Medicines Agency (EMEA) has granted Dacogen …See details»
Eisai buys MGI Pharma for $3.9bn - Financial Times
Dec 11, 2007 · Eisai, Japan’s fourth largest drugsmaker, said Monday it would buy US biotech firm MGI Pharma for $3.9bn in the largest ever overseas all-cash acquisition by a Japanese …See details»
MGI Pharma on acquisition spree, now its Aesgen's turn
Sep 4, 2004 · MGI Pharma Inc, an oncology-focused biopharmaceutical company, and Aesgen, Inc, a privately held company focused on treating side effects associated with cancer …See details»
MGI Pharma | The Pharmaletter
Oct 15, 2000 · Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily …See details»
Gliadel® Wafer demonstrates long-term surviva | EurekAlert!
Mar 8, 2006 · Gliadel Wafer is approved by the FDA for treatment of patients with newly-diagnosed high-grade malignant glioma as an adjunct to surgery and radiation. Gliadel Wafer …See details»
Generative AI in the pharmaceutical industry | McKinsey
Jan 9, 2024 · Generative AI is transforming nearly all aspects of the pharmaceutical industry, revamping the way companies operate and potentially unlocking billions of dollars in value.See details»